Table 2. Treatment Patterns During Index and Switched Treatment.
| All Patients | Patients With CS | |||
| During Index Treatment (on Index LA-SSA) | Lanreotide | Octreotide LAR | Lanreotide | Octreotide LAR |
| (n = 241), n (%) | (n = 521), n (%) | (n = 91), n (%) | (n = 240), n (%) | |
| Reason for end of index treatment, n (%) | ||||
| Switch to other LA-SSA | 6 (2.5) | 39 (7.5) | 4 (4.4) | 20 (8.3) |
| Discontinuation of index LA-SSA | 84 (34.9) | 235 (45.1) | 32 (35.2) | 101 (42.1) |
| End of continuous enrollment | 94 (39.0) | 176 (33.8) | 35 (38.5) | 87 (36.3) |
| End of the study period | 57 (23.7) | 71 (13.6) | 20 (22.0) | 32 (13.3) |
| Patients with 1st dose escalation (n, %) | 15 (6.2) | 142 (27.3) | 9 (9.9) | 84 (35.0) |
| Months from initiation to 1st escalation | ||||
| Mean (SD) | 11.6 (17.2) | 7.6 (7.8) | 16.7 (20.9) | 8.2 (8.8) |
| Median | 4.4 | 4.3 | 4.4 | 4.1 |
| Patients with 2nd dose escalation (n, %) | 2 (0.8) | 27 (5.2) | 2 (2.2) | 18 (7.5) |
| Months from initiation to 2nd escalation | ||||
| Mean (SD) | 1.9 (0.0) | 16.5 (14.1) | 1.9 (0.0) | 17.1 (17.0) |
| Median | 1.9 | 11.2 | 1.9 | 10.1 |
| Months from 1st to 2nd escalation | ||||
| Mean (SD) | 1.0 (0.0) | 9.1 (11.3) | 1.0 (0.0) | 8.9 (13.4) |
| Median | 1.0 | 7.0 | 1.0 | 4.3 |
| Use of other NET treatments,a n (%) | 78 (32.4) | 156 (29.9) | 29 (31.9) | 85 (35.4) |
| Short-acting octreotide | 19 (7.9) | 75 (14.4) | 11 (12.1) | 41 (17.1) |
| Targeted therapy | 26 (10.8) | 51 (9.8) | 8 (8.8) | 28 (11.7) |
| Cytotoxic therapy | 24 (10.0) | 38 (7.3) | 6 (6.6) | 22 (9.2) |
| Lutetium 177Lu-dotatate | 12 (5.0) | 28 (5.4) | 5 (5.5) | 18 (7.5) |
| Telotristat | 16 (6.6) | 20 (3.8) | 9 (9.9) | 16 (6.7) |
| All Patients | Patients With CS | |||
| During Switched Treatment (Transition to Non-index LA-SSA)b | Lanreotide to Octreotide LAR | Octreotide LAR to Lanreotide | Lanreotide to Octreotide LAR | Octreotide LAR to Lanreotide |
| (n = 10), n (%) | (n = 67), n (%) | (n = 9), n (%) | (n = 33), n (%) | |
| Months from end of index treatment to start of switched treatment | ||||
| Mean (SD) | 3.8 (10.1) | 1.9 (4.2) | 4.2 (10.6) | 0.9 (2.7) |
| Median | 0.5 | 0.2 | 0.5 | 0.1 |
| Reason for end of switched treatment, n (%) | ||||
| Switch back to index LA-SSA | 3 (30.0) | 2 (3.0) | 2 (22.2) | 1 (3.0) |
| Discontinuation of other LA-SSA | 3 (30.0) | 20 (29.9) | 3 (33.3) | 11 (33.3) |
| End of continuous enrollment | 3 (30.0) | 28 (41.8) | 3 (33.3) | 13 (39.4) |
| End of the study period | 1 (10.0) | 17 (25.4) | 1 (11.1) | 8 (24.2) |
| Switched treatment durationc (mo) | ||||
| Mean (SD) | 15.6 (14.5) | 17.0 (14.3) | 16.5 (15.0) | 18.0 (15.8) |
| Median | 7.3 | 11.5 | 7.7 | 13.0 |
| Patients with 1st dose escalation, n (%) | 2 (20.0) | 1 (1.5) | 2 (22.2) | 0 (0.0) |
| Months from initiation to 1st escalation | ||||
| Mean (SD) | 13.9 (3.1) | 22.3 | 13.9 (3.1) | |
| Median | 13.9 | 22.3 | 13.9 | |
| Patients with 2nd dose escalation, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Use of other NET treatments,a n (%) | 6 (60.0) | 25 (37.3) | 5 (55.6) | 19 (57.6) |
| Short-acting octreotide | 4 (40.0) | 7 (10.4) | 3 (33.3) | 5 (15.2) |
| Targeted therapy | 1 (10.0) | 10 (14.9) | 1 (11.1) | 7 (21.2) |
| Cytotoxic therapy | 1 (10.0) | 6 (9.0) | 1 (11.1) | 3 (9.1) |
| Lutetium 177Lu-dotatate | 4 (40.0) | 3 (4.5) | 3 (33.3) | 2 (6.1) |
| Telotristat | 2 (20.0) | 5 (7.5) | 2 (22.2) | 4 (12.1) |
aNET treatments (other than LA-SSA) include targeted therapies (belzutifan, everolimus, sunitinib), cytotoxic chemotherapies (capecitabine, carboplatin, cisplatin, dacarbazine, doxorubicin, etoposide, fluorouracil, ipilimumab, irinotecan, leucovorin, nivolumab, oxaliplatin, pembrolizumab, streptozotocin, temozolomide), interferon alfa-2b (not observed in the study), lutetium 177Lu-dotatate, and telotristat. Patients could have more than one of these other NET treatments (the categories are not mutually exclusive).
bPatients could switch immediately (ie, index treatment ended due to switch to the other LA-SSA) or sometimes later after the end of index treatment. Patients were included in switched treatment reporting if they ended index treatment during follow-up, switched to the other LA-SSA after index treatment, remained on that switched treatment for ≥3 months, and had claims data supporting dose escalation analysis during the switched treatment.
cDuration of therapy was not adjusted for patients whose follow-up ended prior to the end of LA-SSA treatment. Duration was defined from the start of treatment until the first of a gap of >60 days in treatment, switching to the other LA-SSA, or end of follow-up.
Abbreviations: CS, carcinoid syndrome; LAR, long-acting release; LA-SSA, long-acting somatostatin analog.